Four women, aged 52 to 76 years, with type 2 diabetes who were in danger of vision loss due to severe DME were included in this prospective, non-comparative case series. They all used oral antidiabetic agents for 14 to 20 years, while one patient required exogenous insulin therapy for the last 4 years. Patients were free of other major medical disorders and they had no evidence of infection. Following full discussion and after obtaining informed consent, 2 infusions of infliximab (5mg/kg, Remicade, Schering-Plough, Greece) with one month interval, were given intravenously over 3 hours in an outpatient setting on a compassionate basis. Additional infusions were offered in 3 patients. Concomitant medications remained unchanged.